US-licensed Avastin

BIOLOGICAL2 trials

Sponsors

Celltrion, Zhejiang Teruisi Pharmaceutical Inc.

Conditions

Healthy

Phase 1

To Demonstrate Similarity of Pharmacokinetics and Evaluate Safety of CT-P16, EU-Approved Avastin and US-licensed Avastin

CompletedNCT03247673

CelltrionHealthy

Start: 2017-08-07End: 2018-01-17Updated: 2020-03-26

A Study to Compare Pharmacokinetic and Safety of TRS003 to China-approved Bevacizumab and US-licensed Avastin®

CompletedNCT03882424

Zhejiang Teruisi Pharmaceutical Inc.Healthy

Start: 2018-06-12End: 2018-10-25Updated: 2020-06-16

Related Papers

Population Pharmacokinetic Comparability of CT-P16 Versus EU-Avastin<sup>®</sup> and US-Avastin<sup>®</sup> in Healthy Subjects and Patients with Non-Squamous Non-Small Cell Lung Cancer.

2026-08-02

Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial.

2022-09-289 citations

A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males.

2019-04-0115 citations